Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-BCMA + huCART19
- Development stage
- Phase 1
- Lead developer
- University of Pennsylvania
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CART-BCMA + huCART19 is an investigational combination autologous cellular immunotherapy being developed by the University of Pennsylvania in collaboration with Novartis. This dual-targeting approach consists of two distinct CAR T-cell products: CART-BCMA, which targets B-cell maturation antigen (BCMA), and huCART19 (also known as CTL119), which targets CD19. Both products are autologous T cells engineered via lentiviral transduction to express chimeric antigen receptors (CARs) containing 4-1BB and CD3ζ signaling domains. By targeting both BCMA and CD19, the therapy aims to address the heterogeneity of antigen expression on malignant plasma cells and potentially eliminate myeloma progenitor cells. The combination is currently being evaluated in a Phase 1 clinical trial (NCT03549442) for patients with high-risk multiple myeloma, either as a consolidation strategy following first- or second-line therapy or for relapsed/refractory disease responding to salvage therapy.
- Other names
- CART-BCMA with huCART19huCART19 + CART-BCMACAR T BCMA + huCART19
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CART-BCMA + huCART19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-BCMA + huCART19.